The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Completed · Phase 1
Conditions studied: Solid Tumors
In brief
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
Key facts
- Study ID
- NCT02660034
- Run by
- BeiGene
- People needed
- 229
- Starts
- 2016-02-02
- Expected to finish
- 2020-09-09
- Last updated by the study team
- 2021-12-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Pinnacle Oncology Hematology — Scottsdale, Arizona, United States
- Cedars Sinai Medical Center — Los Angeles, California, United States
- Rocky Mountain Cancer Centers — Denver, Colorado, United States
- Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- Texas Oncology — Dallas, Texas, United States
- Texas Oncology — Tyler, Texas, United States
- Virginia Cancer Specialists — Fairfax, Virginia, United States
- The Canberra Hospital — Garran, Australian Capital Territory, Australia
- Mid North Coast Cancer Institute — Coffs Harbour, New South Wales, Australia
- Calvary Mater Newcastle — Newcastle, New South Wales, Australia
- Westmead Hospital — Parramatta, New South Wales, Australia
- Prince of Wales — Randwick, New South Wales, Australia
- Northern Cancer Institute — St Leonards, New South Wales, Australia
- Icon Cancer Care — Brisbane, Queensland, Australia
- Monash Health — Clayton, Victoria, Australia
- Peter MacCallum Cancer Centre — Melbourne, Victoria, Australia
- Linear Clinical Research Ltd — Nedlands, Western Australia, Australia
- Institut Gustave Roussy — Paris, France
- Centre Eugene Marquis — Rennes, France
- Auckland City Hospital — Auckland, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.